A 2-year study of lipid and lipoprotein changes in postmenopausal women with tibolone and estrogen-progestin

Milner, M; Sinnott, Margaret; Cooke, Tommy M.; Kelly, A.C.; McGill, Tony; Harrison, Robert F.

doi:10.1016/0029-7844(95)00468-8

Cited by 52 publications

(18 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, they also consistently reduce plasma total cholesterol and lipoprotein(a). In addition, tibolone reduces plasma triglycerides, whereas continuous combined EJNETA reduces plasma LDL‐C, all changes which protect against cardiovascular disease 23–27 . Since the relative contribution of alterations in individual lipid fractions on the risk of cardiovascular disease is unknown and since the alterations in lipid metabolism associated with HRT contribute 30% to the reduction of cardiovascular diseas 28 , the overall effect of these two preparations cannot exactly be determined.…”

Section: Discussionmentioning

confidence: 99%

A double‐blind, randomised trial comparing the effects of tibolone and continuous combined hormone replacement therapy in postmenopausal women with menopausal symptoms

Hammar¹,

Christau²,

Nathorst-Böös

et al. 1998

BJOG

167

View full text Add to dashboard Cite

Objective To compare the effects of two postmenopausal regimens on menopausal symptoms, bleeding episodes, side effects and acceptability.Design Double-blind, randomised controlled trial.Setting Twenty-nine sites in Denmark, nine in Norway and six in Sweden.Participants Four hundred and thirty-seven postmenopausal women with menopausal complaints. None of these women had had a hysterectomy.Interventions Daily treatment with tibolone 2.5 mg (n = 218) or l7p-oestradiol 2 mg plus norethisterone acetate 1 mg (E,lNETA) (n = 219). Main outcome measures Hot flushes, sweating episodes, vaginal dryness, assessment of sexual life and bleeding patterns; at baseline and after 4, 12,24 and 48 weeks.Results Treatment with either preparation significantly reduced mean scores for hot flushes, sweating episodes and vaginal dryness. The overall discontinuation rate was 28% (tibolone 25%, E,/NETA 31%; P = 0.14), mostly during the first six months. There was a markedly lower cumulative incidence of bleeding or spotting episodes with tibolone compared with E,/NETA ( P < O.OOOl), mainly during the first six treatment cycles. Conclusions Both tibolone and E,/NETA effectively alleviate menopausal symptoms. However, tibolone caused significantly fewer bleeding or spotting episodes, which were reflected by lower overall rates of bleeding, as well as lower drop-out rates due to bleeding.

show abstract

Section: Discussionmentioning

confidence: 99%

A double‐blind, randomised trial comparing the effects of tibolone and continuous combined hormone replacement therapy in postmenopausal women with menopausal symptoms

Hammar¹,

Christau²,

Nathorst-Böös

et al. 1998

BJOG

167

View full text Add to dashboard Cite

show abstract

“…2). When the studies were categorized according to the dose of Milner et al [38] Ostberg et al [39] Perrone et al [ (Fig. 3).…”

Section: Effect Of Tibolone On Plasma Lp(a) Concentrationsmentioning

confidence: 99%

Tibolone decreases Lipoprotein(a) levels in postmenopausal women: A systematic review and meta-analysis of 12 studies with 1009 patients

et al. 2015

View full text Add to dashboard Cite

show abstract

“…Its main advantage over estrogen therapy appears to be the lower incidence of vaginal bleeding and breast tenderness 116 . The major disadvantages of tibilone therapy compared with that of estrogen therapy is its less favorable effects on serum lipid profile, which may result in decreased cardioprotective effects 117,118 . Long‐term tibilone therapy is not associated with a decrease in LDL cholesterol as occurs with estrogen therapy, and it maintains or reduces the pretreatment levels of HDL cholesterol (whereas estrogen therapy increases it) 52 , 119 .…”

Section: Sex Steroids In the Management Of Osteoporosismentioning

confidence: 99%

“…116 The major disadvantages of tibilone therapy compared with that of estrogen therapy is its less favorable effects on serum lipid profile, which may result in decreased cardioprotective effects. 117,118 Long-term tibilone therapy is not associated with a decrease in LDL cholesterol as occurs with estrogen therapy, and it maintains or reduces the pretreatment levels of HDL cholesterol (whereas estrogen therapy increases it). 52,119 However, like estrogen, tibilone reduces the serum concentration of lipoprotein(a), an independent risk factor for coronary artery disease.…”

Section: Tibilonementioning

confidence: 99%

Hormone Replacement Therapy and Fractures in Older Adults

Kamel

Perry

Morley

2001

J American Geriatrics Society

View full text Add to dashboard Cite

Estrogen deficiency in women is associated with accelerated bone loss, and estrogen replacement therapy has been proven to be effective in preventing osteoporosis and fractures in postmenopausal women. The introduction of selective estrogen receptor modulators that have an estrogen-like effect on the skeleton but have a different pattern of effects on other tissues may have an important role in the management of osteoporosis in women in the near future. In men, androgen deficiency has been shown to be associated with osteoporosis. Although androgen replacement in hypogonadal men may decrease bone resorption and increase bone mass, long-term placebo-controlled trials are needed to better define the benefits and risks of such therapy before it can be recommended. Sex hormone deficiency is linked to the development of osteoporosis in both women and men. In women, hormonal replacement by estrogen or the newly developed selective estrogen receptor modulators may prevent the development of osteoporosis and its related fractures. In men, there is early evidence that testosterone replacement therapy may enhance bone mass in hypogonadal men.

show abstract

A 2-year study of lipid and lipoprotein changes in postmenopausal women with tibolone and estrogen-progestin

Abstract: Some changes accompanying tibolone may be favorable and may counter its adverse effect on HDL cholesterol. Lowering of lipoprotein (a) was the only significant change found with estrogen-progestin.

Cited by 52 publications

References 18 publications

A double‐blind, randomised trial comparing the effects of tibolone and continuous combined hormone replacement therapy in postmenopausal women with menopausal symptoms

A double‐blind, randomised trial comparing the effects of tibolone and continuous combined hormone replacement therapy in postmenopausal women with menopausal symptoms

Tibolone decreases Lipoprotein(a) levels in postmenopausal women: A systematic review and meta-analysis of 12 studies with 1009 patients

Hormone Replacement Therapy and Fractures in Older Adults

Contact Info

Product

Resources

About